Clinical trial
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple…
NCT00220779 · Grifols Therapeutics LLC, Industry · Completed
Key facts
| NCT number | NCT00220779 |
|---|---|
| Title | Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis |
| Official title | Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV Chromatography (IGIV-C), 10% Treatment on Relapses in Patients With Relapsing Remitting Multiple Sclerosis |
| Acronym | PRIVIG |
| Lead sponsor | Grifols Therapeutics LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP) |
| Enrollment | 128 |
| Start date | Dec 1, 2002 |
| Primary completion | Feb 1, 2005 |
| Completion | Feb 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 27, 2016 |
| Countries | Austria, Canada, Czechia, Germany, Greece, Hungary, Israel, Poland, Slovakia, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: